Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Medicinova (MNOV) Cost of Revenue (2025)

Medicinova (MNOV) has disclosed Cost of Revenue for 3 consecutive years, with $146985.0 as the latest value for Q4 2025.

  • Quarterly Cost of Revenue changed N/A to $146985.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at $378606.0 for FY2025, N/A changed from the prior year.
  • Cost of Revenue for Q4 2025 was $146985.0 at Medicinova, up from $115272.0 in the prior quarter.
  • The five-year high for Cost of Revenue was $146985.0 in Q4 2025, with the low at $115272.0 in Q3 2025.